|1.||Dohi, Toshihiro: 2 articles (01/2014 - 10/2004)|
|2.||Morita, Katsuya: 2 articles (01/2014 - 10/2004)|
|3.||Laurenzana, A: 2 articles (06/2006 - 03/2005)|
|4.||Pancrazzi, A: 2 articles (06/2006 - 03/2005)|
|5.||Paoletti, F: 2 articles (06/2006 - 03/2005)|
|6.||Vannucchi, A M: 2 articles (06/2006 - 03/2005)|
|7.||Cellai, C: 2 articles (06/2006 - 03/2005)|
|8.||Kato, Masatomo: 2 articles (08/2004 - 08/2003)|
|9.||Miyaji, Suguru: 2 articles (08/2004 - 08/2003)|
|10.||Oda, Tomoko: 2 articles (08/2004 - 08/2003)|
|1.||Allergic Conjunctivitis (Giant Papillary Conjunctivitis)
08/01/2004 - "The purpose of the present studies is to elucidate the role of PAF in eosinophil activation at conjunctiva and to confirm the efficacy of Apafant (a potent PAF antagonist) ophthalmic solution in chronic experimental allergic conjunctivitis. "
08/01/2004 - "From the instillation of PAF solution into guinea pig eyes, which were in a state of chronic allergic conjunctivitis, a significant increase in EPO activity was observed, and this increase was inhibited by pre-treatment with Apafant. "
08/01/2003 - "These results clearly indicate that apafant has potential as a topical ocular anti-PAF for treating allergic conjunctivitis."
08/01/2004 - "Apafant, a potent platelet-activating factor antagonist, blocks eosinophil activation and is effective in the chronic phase of experimental allergic conjunctivitis in guinea pigs."
08/01/2003 - "The role of platelet activating factor and the efficacy of apafant ophthalmic solution in experimental allergic conjunctivitis."
|2.||Asthma (Bronchial Asthma)
10/01/1997 - "These findings suggest that apafant may be effective in nonspecific airway hyperreactivity in asthma."
02/01/1991 - "We conclude that WEB 2086 is capable of preventing the development of LAR and increase in AH, and thus PAF may play an important causal role in LAR and increased AH observed in asthma."
02/01/1990 - "WEB 2086 should be of value in further elucidation of the role of endogenous PAF in asthma through activation of inflammatory cells recruited to the lung."
05/01/1994 - "The inhaled corticosteroid dose required for symptomatic control of asthma was established and further steroid reduction was attempted after treatment with WEB 2086 40 mg three times daily for 12 wk. Of 106 patients recruited, 68 entered the treatment phase and 65 completed 6 wk of treatment. "
01/01/1996 - "Effect of a potent platelet-activating factor antagonist, WEB-2086, on asthma. "
05/01/1997 - "LPS was then administered without an earlier episode of traumatic shock to animals treated with WEB-2086 or vehicle. "
02/01/1989 - "Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock."
02/01/1989 - "We have investigated the role of platelet activating factor (PAF) in the pathogenesis of a murine model of traumatic shock using WEB 2086, a specific antagonist of PAF. "
05/01/1997 - "In the absence of traumatic shock, WEB-2086 was associated with reduced mortality (four of five WEB-2086 treated pigs versus two of five vehicle pigs survived 5 hours; p = 0.07) and improved arterial PO2 (p = 0.05) and base excess (p = 0.04) 60 minutes after LPS administration. "
12/01/2000 - "The purpose of this study was to examine the efficacy of WEB 2086 in attenuating leukocyte adherence before, during, and after hemorrhagic shock. "
12/01/2000 - "Our findings suggest that WEB 2086 may be of therapeutic benefit against the microvascular damage sustained after hemorrhagic shock."
12/01/2000 - "This effect of WEB 2086 on adherence could be demonstrated even when it was given during (3.5 +/- 0.9 cells/100 microm, p < 0.01) and 10 minutes into (5.8 +/- 1.1 cells/100 microm, p < 0.05) hemorrhagic shock. "
12/01/2000 - "WEB 2086 is a PAF antagonist that has been shown experimentally to improve survival after hemorrhagic shock. "
12/01/2000 - "Effect of WEB 2086 on leukocyte adherence in response to hemorrhagic shock in rats."
|5.||Anaphylaxis (Anaphylactic Shock)
06/01/1992 - "3. Anaphylaxis-induced decreases in blood flow to the adrenals were effectively antagonized by WEB 2086, although this antagonist did not reverse blood flow decreases to any other tissues. "
08/21/1987 - "In contrast, WEB 2086 was ineffective against active anaphylaxis in vivo. "
04/01/1987 - "In mice a lethal anaphylactic shock and a PAF-induced (100 micrograms/kg i.v.) death was inhibited by i.v. WEB 2086. "
07/01/1990 - "In conclusion, WEB 2086 was found to exert marked protective effects against PAF related cardiac arrhythmias, indicating its potential usefulness for the treatment of cardiac anaphylaxis."
04/01/1987 - "In contrast, in passively sensitized animals a dose-dependent inhibition of the pulmonary (bronchoconstriction) and blood pressure (hypotension) reaction due to anaphylaxis was achieved by i.v. WEB 2086. "
|1.||WEB 2086 (apafant)
|2.||Platelet Activating Factor
|3.||Histamine (Histamine Dihydrochloride)
|6.||Interleukin-8 (Interleukin 8)
|8.||Acetic Acid (Vinegar)
|10.||Interleukin-5 (Interleukin 5)
|5.||Drug Therapy (Chemotherapy)